This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2024 Sep 5;391(9):867-869.

doi: 10.1056/NEJMc2408786.

BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease

Melanie Hagen¹, Laura Bucci¹, Sebastian Böltz¹, Danae-Mona Nöthling¹, Tobias Rothe¹, Kirill Anoshkin¹, Maria G Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Christina Düsing², Jörg H W Distler², Torsten Kuwert³, Aline Bozec³, Andreas Ramming³, Georg Schett³, Ricardo Grieshaber-Bouyer³

Affiliations

Affiliations

¹ Friedrich Alexander University Erlangen-Nuremberg , Erlangen, Germany.
² Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
³ Friedrich Alexander University Erlangen-Nuremberg , Erlangen, Germany ricardo.grieshaber@fau.de.

PMID: 39231353
DOI: 10.1056/NEJMc2408786

BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease

Melanie Hagen et al. N Engl J Med. 2024.

. 2024 Sep 5;391(9):867-869.

doi: 10.1056/NEJMc2408786.

Authors

Melanie Hagen¹, Laura Bucci¹, Sebastian Böltz¹, Danae-Mona Nöthling¹, Tobias Rothe¹, Kirill Anoshkin¹, Maria G Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Christina Düsing², Jörg H W Distler², Torsten Kuwert³, Aline Bozec³, Andreas Ramming³, Georg Schett³, Ricardo Grieshaber-Bouyer³

Affiliations

¹ Friedrich Alexander University Erlangen-Nuremberg , Erlangen, Germany.
² Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
³ Friedrich Alexander University Erlangen-Nuremberg , Erlangen, Germany ricardo.grieshaber@fau.de.

PMID: 39231353
DOI: 10.1056/NEJMc2408786

No abstract available

PubMed Disclaimer

Similar articles

BCMA-targeted immunotherapy for multiple myeloma.
Yu B, Jiang T, Liu D. Yu B, et al. J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7. J Hematol Oncol. 2020. PMID: 32943087 Free PMC article. Review.
Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells.
Supimon K, Sangsuwannukul T, Luangwattananun P, Yenchitsomanus PT. Supimon K, et al. Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113480. doi: 10.1016/j.intimp.2024.113480. Epub 2024 Oct 29. Int Immunopharmacol. 2024. PMID: 39467352
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. Hipp S, et al. Leukemia. 2017 Aug;31(8):1743-1751. doi: 10.1038/leu.2016.388. Epub 2016 Dec 27. Leukemia. 2017. PMID: 28025583
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. Shah N, et al. Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13. Leukemia. 2020. PMID: 32055000 Free PMC article. Review.
An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS, Schulman AD, Choi SH, Rodgers DT, Kazane SA, Kim CH, Lawson BR, Young TS. Ramadoss NS, et al. J Am Chem Soc. 2015 Apr 29;137(16):5288-91. doi: 10.1021/jacs.5b01876. Epub 2015 Apr 15. J Am Chem Soc. 2015. PMID: 25826669

See all similar articles

Cited by

RNA-ssisting immunity to heal the heart: a new frontier in therapeutics.
Rurik JG, Le Phu C, Mustroph J, Buggert M. Rurik JG, et al. Cardiol Plus. 2025 Apr-Jun;10(2):129-144. doi: 10.1097/CP9.0000000000000116. Epub 2025 Jun 24. Cardiol Plus. 2025. PMID: 40599556 Free PMC article. Review.
B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells.
Menzel SR, Roth E, Wittner J, Brey S, Weckwerth L, Thomas J, Winkler TH, Schuh W, Jäck HM, Pracht K, Schulz SR. Menzel SR, et al. Nat Commun. 2025 Aug 2;16(1):7106. doi: 10.1038/s41467-025-62530-2. Nat Commun. 2025. PMID: 40753161 Free PMC article.
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.
Alexander T, Roldan E, Del Papa N, Farge D, Henes J, Marjanovic Z, Puyade M, Snowden JA, Spierings J, de Vries-Bouwstra JK, Onida F, Ruggeri A, Sánchez-Ortega I, Burt R, Cervera R, Doria A, Moore J, Oliveira MC, Pugnet G, Rimar D, Schmalzing M, Yakoub-Agha I, Greco R. Alexander T, et al. Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02695-y. Online ahead of print. Bone Marrow Transplant. 2025. PMID: 40830237
[Acute inpatient rheumatology in Germany : Indispensable part of rheumatology care and specialist training].
Pfeil A, Fleck M, Lorenz HM, Müller-Ladner U, Lakomek HJ, Specker C. Pfeil A, et al. Z Rheumatol. 2025 Sep 2. doi: 10.1007/s00393-025-01714-z. Online ahead of print. Z Rheumatol. 2025. PMID: 40892225 Review. German.
Advances in the treatment of systemic lupus erythematosus.
Scherlinger M, Kolios AGA, Kyttaris VC, Tsokos GC. Scherlinger M, et al. Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0. Online ahead of print. Nat Rev Drug Discov. 2025. PMID: 40676245 Review.

See all "Cited by" articles

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program